Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Extra Hixenin

Research Leaders

6 sponsors active, led by Centre International de la Recherche sur le Cancer

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02730611Completed

Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma

NCT02204813Phase 1Completed

To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery

Showing all 2 trials

Research Network

Common Treatments

  • Extra Hixenin1
  • Hixenin1
  • Loxenin1

Active Sponsors

  • Centre International de la Recherche sur le Cancer1
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1
  • National Cancer Institute, France1
  • Washington University School of Medicine1
  • Assistance Publique - Hôpitaux de Paris1

Top Investigators

Related Conditions

  • Rouxeny Gastric Bypass1
  • Morbid Obesity1
  • Gastric Banding1
  • Hepatocellular Carcinoma1
  • Cholangiocarcinoma1

Activity Timeline